End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
771,000 KRW | -0.52% | +0.13% | +1.45% |
04-25 | Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe | MT |
04-25 | Samsung Biologics Posts Higher Q1 Profit, Sales | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.45% | 40.51B | |
-3.79% | 88.14B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-14.38% | 12.07B | |
-9.12% | 11.97B | |
-42.56% | 11.61B | |
+4.87% | 8.81B | |
-4.33% | 8.5B |
- Stock Market
- Equities
- A207940 Stock
- News Samsung Biologics Co.,Ltd.
- Samsung Biologics : C&T's Q4 Net Profit Declines 24% on Lower Equity Gains, Higher Costs; Shares Drop 4%